Hidradenitis Suppurativa Market Report 2026

Hidradenitis Suppurativa Market Overview

• Hidradenitis Suppurativa market size has reached to $1.24 billion in 2025 • Expected to grow to $1.75 billion in 2030 at a compound annual growth rate (CAGR) of 7% • Growth Driver: The Rise In The Prevalence Of Skin Diseases • Market Trend: Transforming Hidradenitis Suppurativa Treatment Through Innovative Therapies • North America was the largest region in 2025.

What Is Covered Under Hidradenitis Suppurativa Market?

Hidradenitis suppurativa (HS) is a chronic skin condition that causes painful lumps deep in the skin, usually on parts of the body where skin touches the skin, such as the armpits, inner thighs, and groin area. These lumps frequently appear where skin contacts skin, such as the armpits, inner thighs, and groin. The main types of skin conditions in hidradenitis suppurativa are folliculitis, pimples, boils, and deep acne. Folliculitis refers to a common skin condition that occurs when hair follicles become inflamed or infected, and various types of treatments are used for folliculitis, such as creams, pills, and laser hair removal treatments. The product types included are tablets and intravenous (IV) injections, which are administered through oral and parenteral routes in treatments such as medications, surgery, photodynamic therapy (PDT), laser treatment, and others. The end users are hospitals, specialty clinics, homecare, and others.

What Is The Hidradenitis Suppurativa Market Growth Forecast?

The hidradenitis suppurativa market size is expected to see strong growth in the next few years. It will grow to $1.75 billion in 2030 at a compound annual growth rate (CAGR) of 7.0%. The growth in the forecast period can be attributed to growing demand for targeted biologic drugs, increasing focus on long-term disease management, expansion of personalized dermatology care, rising adoption of advanced laser therapies, increasing investment in chronic skin disease research. Major trends in the forecast period include increasing adoption of biologic therapies for hs, rising use of minimally invasive surgical treatments, growing focus on early disease diagnosis, expansion of combination treatment approaches, enhanced patient-centric care models.

Global Hidradenitis Suppurativa Market Segmentation

1) By Disease Severity: Hurley Stage I, Hurley Stage II, Hurley Stage III 2) By Treatment: Medications, Surgical Treatment 3) By Route of Administration: Oral, Subcutaneous, Topical 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Pharmacies 5) By End User: Hospitals, Dermatology Clinics Or Specialty Clinics, Ambulatory Surgical Centers Subsegments: 1) By Medications: Antibiotics, Biologics, Hormonal Therapy, Immunosuppressants, Retinoids 2) By Surgical Treatment: Incision and Drainage, Deroofing, Wide Excision, Laser & Light-Based Therapy

What Is The Driver Of The Hidradenitis Suppurativa Market?

The rise in the prevalence of skin diseases is driving the growth of the hidradenitis suppurativa market going forward. Skin diseases refer to a wide range of skin problems, including those attributed to bacterial infections, viral infections, fungal infections, allergy symptoms, skin malignancies, and parasites. Hidradenitis suppurativa (HS), a chronic and severe skin disorder, is driving the development of new products and services for its management due to increased awareness, accurate diagnosis, a growing patient pool, and research advancements. For instance, in January 2024, according to the American Cancer Society, a US-based non-profit organization dedicated to eliminating cancer, there will be 108,270 reported cases of skin cancer, reflecting a 3.2% increase from the 104,930 cases reported in 2023. Therefore, the rise in the prevalence of skin diseases propels the growth of the hidradenitis suppurativa industry.

Key Players In The Global Hidradenitis Suppurativa Market

Major companies operating in the hidradenitis suppurativa market are AbbVie Inc., Pfizer Inc., Johnson & Johnson, Novartis AG, Eli Lilly and Company, UCB S.A., LEO Pharma A/S, Almirall S.A., AstraZeneca plc, Bayer AG, Otsuka Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Ltd., Taro Pharmaceutical Industries Ltd., AnaptysBio Inc., Acelyrin Inc., Arcutis Biotherapeutics Inc., Priovant Therapeutics, Aristea Therapeutics, Union Therapeutics, Revance Therapeutics

Global Hidradenitis Suppurativa Market Trends and Insights

Major companies operating in the hidradenitis suppurativa market are focusing on developing advanced biologic therapies to improve treatment outcomes and address unmet medical needs. Biologics are medications derived from living organisms that target specific components of the immune system involved in disease progression. For instance, in June 2023, Novartis AG, a Switzerland-based pharmaceutical company, received European regulatory approval for Cosentyx for hidradenitis suppurativa. Cosentyx is the first and only fully human biologic that specifically inhibits interleukin-17A, a key cytokine implicated in hidradenitis suppurativa. With over 14 years of clinical research, Cosentyx provides a well-established and targeted therapeutic option, reinforcing Novartis’s position in the hidradenitis suppurativa market.

What Are Latest Mergers And Acquisitions In The Hidradenitis Suppurativa Market?

In July 2025, Novartis AG, a Switzerland-based pharmaceutical company, reached a milestone agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) to promote access to Cosentyx® for the treatment of hidradenitis suppurativa (HS). The collaboration aims to improve patient access to innovative biologic therapy, enhance treatment outcomes, and support the broader adoption of effective HS management across Canada. The pan-Canadian Pharmaceutical Alliance is a Canada-based non-profit organization that negotiates drug prices on behalf of Canadian public drug plans.

Regional Outlook

North America was the largest region in the hidradenitis suppurativa market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Hidradenitis Suppurativa Market?

The hidradenitis suppurativa (HS) market consists of revenues earned by entities providing treatment to axillary-mammary-inguinal hidradenitis suppurativa, follicular hidradenitis suppurativa, gluteal hidradenitis suppurativa, and syndromic hidradenitis suppurativa. The market value includes the value of related goods sold by the service provider or included within the service offering. The hidradenitis suppurativa (HS) market also includes sales of surgery biologics, antibiotics, immunosuppressive drugs, zinc supplements, and retinoids. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Hidradenitis Suppurativa Market Report 2026?

The hidradenitis suppurativa market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the hidradenitis suppurativa industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.